Capricor Therapeutics (CAPR) Income from Continuing Operations (2010 - 2026)
Capricor Therapeutics (CAPR) recorded quarterly Income from Continuing Operations of 33941345.0 in Q1 2026, down 25.08% quarter-over-quarter from 27134794.0 in Q4 2025, and down 39.15% on a YoY basis from 55780370.88 in Q1 2025.
Capricor Therapeutics (CAPR) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Capricor Therapeutics' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 33941345.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 39.15% year-over-year to 33941345.0; the TTM figure through Mar 2026 stood at 111572462.0 (down 434.04% YoY), while the FY2025 annual figure was 105043946.0, down 159.58% from the prior year.
- Income from Continuing Operations was 33941345.0 for Q1 2026 at Capricor Therapeutics, down from 27134794.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 27055800.0 in Q4 2024 to a low of 33941345.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 11399049.71 across 5 years, with a median of 7818094.0 in 2022.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations jumped 3363.3% in 2024, then sank 200.29% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 7686646.0 in 2022, then surged by 89.21% to 829093.0 in 2023, then surged by 3363.3% to 27055800.0 in 2024, then tumbled by 200.29% to 27134794.0 in 2025, then fell by 25.08% to 33941345.0 in 2026.
- The last three Income from Continuing Operations figures came in at 33941345.0 (Q1 2026), 27134794.0 (Q4 2025), and 24570541.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -56.48 Mn |
| 10 | Capricor Therapeutics | 1.53 Bn | 1.26 Bn | - | -33.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.94 Mn |
| Dec 31, 2025 | -27.13 Mn |
| Sep 30, 2025 | -24.57 Mn |
| Jun 30, 2025 | -25.93 Mn |
| Mar 31, 2025 | -24.39 Mn |
| Dec 31, 2024 | 27.06 Mn |
| Sep 30, 2024 | -12.56 Mn |
| Jun 30, 2024 | -11.00 Mn |
| Mar 31, 2024 | -9.79 Mn |
| Dec 31, 2023 | -829,093.00 |
| Sep 30, 2023 | -6.39 Mn |
| Jun 30, 2023 | -7.37 Mn |
| Mar 31, 2023 | -7.77 Mn |
| Dec 31, 2022 | -7.69 Mn |
| Sep 30, 2022 | -6.37 Mn |
| Jun 30, 2022 | -7.30 Mn |
| Mar 31, 2022 | -7.82 Mn |
| Dec 31, 2021 | -6.36 Mn |
| Sep 30, 2021 | -4.30 Mn |
| Jun 30, 2021 | -5.07 Mn |